All Stories

HHS abruptly terminates funding for Atlanta biotech’s t...

The U.S. government continues to end contacts related to the $5 billion Project ...

Abbott plans to weather tariff storm with investments i...

Abbott said its network of 90 production sites around the world, plus $500 milli...

Fierce Biotech Fundraising Tracker '25: Glycomine gathe...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Fierce Biotech Fundraising Tracker '25: Glycomine gathe...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Glycomine grabs $115M series C to fund phase 2 journey ...

Glycomine has bagged a $115 million series C round to continue the progress of i...

Investor pressures struggling Essa to liquidate, give c...

Essa Pharma is facing a call to wind down operations. Soleus Capital Management,...

Telix points to 'promising' 13-month survival rate in p...

Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation ther...

Johnson & Johnson estimates $400M impact from worldwide...

During its quarterly earnings report, executives at Johnson & Johnson said they ...

Merck inks $493M biobucks deal to use Cyprumed's tech t...

Merck will create oral versions of its peptides using Cyprumed's drug delivery t...

Digital-focused private equity firm BayPine acquires ma...

CenExel is the latest CRO to change ownership hands. Boston-based private equity...

Trump admin freezes more than $2.2B in funding to Harva...

The Trump administration is freezing more than $2.2 billion in funding to Harvar...

Illumina teams up with Tempus to expand DNA profiling b...

The companies said they will work together to train artificial intelligence algo...

Edwards nets mitral valve replacement approval in Europe

After acquiring its developer last year, Edwards Lifesciences has now obtained a...

Spruce smartens up pipeline with deal for BioMarin asse...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMar...

Fierce Biotech Layoff Tracker 2025: Mural lays off 90%;...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Fierce Biotech Fundraising Tracker '25: Attovia attract...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Mural risks going to the wall as IL-2 flop triggers 90%...

The writing is on the wall at Mural Oncology. Responding to clinical data, the b...

NAYA Biosciences spins off cancer drug business 6 month...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAY...

Sanofi's high hopes for $1.1B Kymab anti-inflammatory d...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morni...

Sanofi’s high hopes for $1.1B Kymab anti-inflammatory d...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morni...

Boehringer boards B-cell depletion bandwagon, paying Cu...

Boehringer Ingelheim has joined the surge of companies entering the B-cell deple...

'One of the lucky few': Bicara's CEO on operating in to...

Amid an FDA overhaul and market volatility, one biotech executive says her publi...

Market volatility compounds 'already challenging' year ...

The market turbulence unleashed by President Donald Trump’s tariff policies will...

UK launches one-year rollout of clinical trial regulati...

The U.K. is rolling out new regulations meant to reduce red tape for clinical st...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.